Are Newborn Screening Recommendations Effective?

Evidence-based policy decisions on screening recommendations in infants for rare conditions using the newborn blood spot test is necessary where effective screening programs can save lives.

A new study explores whether screening infants for rare conditions using the newborn blood spot test is effective or not. The findings of the study are reported in The BMJ.

Effective screening programs can save lives, whereas ineffective programs can do more harm than good, yet decisions about which conditions to screen for vary widely between countries, despite similar populations and healthcare systems.

Newborn Screening Expansion Offers Early Diagnosis and Treatment
Newborn screening programs enable early detection of conditions for which prompt treatments can decrease the risk of death or irreversible damage.

‘Evidence-based policy decisions on screening recommendations in infants for rare conditions using the newborn blood spot test is very important because it is difficult to stop once the screening program begins.’

Reasons for these differences are unclear, but it has been suggested that differences in the evidence review process used to generate policy - in particular, the use of systematic reviews - may play a role.

Systematic reviews bring together evidence from existing studies and use statistical methods to summarize the results, to help make evidence-based decisions.

To explore this further, a team of UK researchers assessed whether the use of a systematic review affects national decisions on whether to screen for a range of conditions using the newborn blood spot test, which is offered to every baby to detect rare but serious health conditions.

Newborn Screening Test to Detect 193 Genetic Diseases
Newborn screening test developed by scientists could reveal if your newborn is prone to 193 medical diseases.

Their analysis included 93 reports that assessed 104 conditions across 14 countries, giving a total of 276 recommendations.

Screening was favored in 159 (58%) recommendations, not favored in 98 (36%), and not recommended either way in 19 (7%).

Newborn Screening for Congenital Cytomegalovirus Infection is Cost Effective
Screening newborns for congenital cytomegalovirus infection is associated with cost savings across a wide range of assumptions.

Only 60 (22%) of the recommendations were based on evidence from a systematic review. Use of a systematic review was associated with a reduced probability of screening being recommended (38% v 63%).

Evidence for test accuracy was not considered in 115 (42%) of recommendations, while evidence around the benefits of early detection and the potential harm of over diagnosis were not considered in 83 (30%) and 211 (76%) of recommendations, respectively.

Screening (for Genetic and Other Disorders) of Embryos and Newborns: Why it is important?
Pre-Implantation Genetic Diagnosis (PGD) of embryos and New Born Screening of infants checks metabolic and inherited disorders and ensure proper growth of new born babies.

The researchers point to some study limitations, the key one being that use of systematic review methods may have been driven by country-level factors. However, strengths include a large number of documents analyzed and the ability to take account of potentially influential factors across different conditions.

"This study showed that many national policy decisions about whether to screen for conditions are being made without systematically reviewing the evidence," say the authors. "Yet it remains essential to make evidence-based policy decisions because once screening programs are started, they are difficult to stop."

They call for further research "to understand why policymakers do not employ systematic review methods in their evaluations of evidence" - and they propose a more international collaboration to undertake such reviews.

Source-Eurekalert